This site requires JavaScript and cookies to be enabled.

 

Convenient,
once-daily dosing1,2

Non-stimulant Qelbree is prescribed once-daily (AM or PM) for full 24-hour exposure.1,2

Titrate weekly as needed to optimize ADHD symptom control1,2

 

Children 6 to 11 years1

Dosing in children age 6 to 11 years. Start Qelbree at 100 mg/day superscript 2. Maximum dose is 400 mg/day superscript 2

Titrate Qelbree 100 mg/week over 1 to 3 weeks as needed to reach effective dose1

 

Teens 12 to 17 years1

Dosing in teens age 12 to 17 years. Start Qelbree at 200 mg/day superscript 2. Maximum dose is 400 mg/day superscript 2

Titrate Qelbree 200mg/week over 1 week as needed to reach an effective dose1

 

Adults 18 years and older1

Dosing in adults age 18 and older. Start Qelbree at 200 mg/day superscript 1. Titrate dose to 400 mg/day superscript 1. Maximum dose is 600 mg/day superscript 1

Titrate Qelbree 200 mg/week over 1-2 weeks as needed to reach an effective dose1

Adult phase III (Study P306) Mean dose at EOS (6 weeks) was 504 mg/day (n=354)2

Abbreviations: EOS, end of study.

Dosing safety information1

  • Severe renal impairment: Initiate Qelbree at 100 mg and increase by 50 mg to 100 mg at weekly intervals to a maximum recommended dosage of 200 mg once daily

 

Use this helpful downloadable resource for more information on dosing needs for your patient

Download Now

3 strengths allow for flexible dosing1

Straightforward, easy administration1

Capsule can be taken whole or entire contents can be sprinkled over a spoonful (teaspoon or tablespoon) of soft food (pudding or applesauce). Consume the entire contents of the pudding mixture within 15 minutes or applesauce mixture within 2 hours, without chewing. Do not store for future use.1,2

  • Capsules and their contents should not be cut, crushed, or chewed
  • Can be taken with or without food
  • Dose will depend on response to medication
Qelbree™ (viloxazine extended-release capsules) can be sprinkled over food

Qelbree capsules are available in 3 dosage strengths: 100 mg capsules, 150 mg capsules, and 200 mg capsules.1

100mg Qelbree™ (viloxazine extended-release capsules) capsule
150mg Qelbree™ (viloxazine extended-release capsules) capsule
200mg Qelbree™ (viloxazine extended-release capsules) capsule

Capsules shown are not actual size.

Dosing_Interior_Small

Refills without the need for a new prescription every month

Qelbree, a non-stimulant therapy, offers ADHD multi-symptom control.1,2

You may even be able to prescribe a 90-day supply for more convenience.*

*Subject to any plan restrictions.

You might also be interested in:

Learn about copay Qelbree FAQs 

IMPORTANT SAFETY INFORMATION

INDICATION

Qelbree is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adult and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in [read more] patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all [read more] Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

 

CONTRAINDICATIONS

  • Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis
  • Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range

WARNINGS & PRECAUTIONS

  • Suicidal thoughts and behaviors: Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes
  • Heart rate, blood pressure increases: Qelbree can cause an increase in diastolic blood pressure and heart rate. Assess these measures prior to starting therapy, following increases in dosage, and periodically during therapy
  • Activation of mania, or hypomania: Noradrenergic drugs may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating treatment with Qelbree, screen patients to determine if they are at risk for bipolar disorder. Screening should include a detailed psychiatric history, including a personal or family history of suicide, bipolar disorder, and depression 
  • Somnolence and fatigue: Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, due to potential somnolence (including sedation or lethargy) and fatigue, until they know how they will be affected by Qelbree 

ADVERSE REACTIONS

The most common adverse reactions (≥ 5% and at least twice the rate of placebo for any dose) in patients 6 to 17 years were somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, and irritability, and in adults, insomnia, headache, somnolence, fatigue, nausea, decreased appetite, dry mouth, and constipation. 

PREGNANCY

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Qelbree during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or by visiting www.womensmentalhealth.org/preg. 

Please see full Prescribing Information, including Boxed Warning.

References:

1. Qelbree. Prescribing information. Supernus Pharmaceuticals Inc; 2022.2. Data on file, Supernus Pharmaceuticals.

IMPORTANT SAFETY INFORMATION

INDICATION

Qelbree is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adult and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in [read more] patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all [read more] Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

 

CONTRAINDICATIONS

  • Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis
  • Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range

WARNINGS & PRECAUTIONS

  • Suicidal thoughts and behaviors: Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes
  • Heart rate, blood pressure increases: Qelbree can cause an increase in diastolic blood pressure and heart rate. Assess these measures prior to starting therapy, following increases in dosage, and periodically during therapy
  • Activation of mania, or hypomania: Noradrenergic drugs may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating treatment with Qelbree, screen patients to determine if they are at risk for bipolar disorder. Screening should include a detailed psychiatric history, including a personal or family history of suicide, bipolar disorder, and depression 
  • Somnolence and fatigue: Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, due to potential somnolence (including sedation or lethargy) and fatigue, until they know how they will be affected by Qelbree 

ADVERSE REACTIONS

The most common adverse reactions (≥ 5% and at least twice the rate of placebo for any dose) in patients 6 to 17 years were somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, and irritability, and in adults, insomnia, headache, somnolence, fatigue, nausea, decreased appetite, dry mouth, and constipation. 

PREGNANCY

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Qelbree during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or by visiting www.womensmentalhealth.org/preg. 

Please see full Prescribing Information, including Boxed Warning.